How to manage NMOSD in a 38-year-old?

Question

Hi doctor,

I am 38 years old. A few years back, I lost vision in one eye suddenly, and later I developed weakness in my legs. Tests showed NMOSD with positive AQP4 antibodies. Since then, I have been receiving Rituximab every six months. While it has helped reduce relapses, I still feel fatigue, bladder problems, and constant fear of another attack. Living with this uncertainty is exhausting. Are there newer, safer medications or lifestyle changes that can reduce my risk? And what is the long-term outlook for patients like me?

Please guide.

Thank you.

Answer 1

Hi,

Welcome to icliniq.com.

I read your query and understand your concerns.

Neuromyelitis optica spectrum disorder (NMOSD) is a chronic autoimmune condition where the immune system attacks the optic nerves and spinal cord, and the fact that you tested positive for aquaporin-4 antibodies confirms the diagnosis.

Rituximab has been a standard and effective treatment to reduce relapses, but as you describe, fatigue, bladder dysfunction, and the anxiety of relapse are common ongoing challenges even when attacks are fewer.

In recent years, newer targeted therapies have been approved that will provide alternatives or additions to Rituximab. These include Eculizumab, which blocks the complement system involved in the autoimmune attack, Inebilizumab, which depletes B cells similar to Rituximab but with a broader effect, and Satralizumab, which targets the interleukin-6 pathway.

These drugs have shown strong efficacy in reducing relapses, though each comes with its own safety considerations, cost, and monitoring requirements, so your neurologist can help weigh the options based on your health profile.

In terms of lifestyle, pacing your daily activities, ensuring good sleep, avoiding overheating, staying active with gentle exercise, and working with physiotherapists or occupational therapists can help manage fatigue and mobility issues.

Bladder symptoms often improve with urologist-guided management, hydration strategies, and in some cases, medications. The long-term outlook for NMOSD has improved significantly with modern therapies, as relapses can now be largely prevented in many patients, which reduces the risk of severe vision loss or paralysis.

While the unpredictability of the disease is emotionally taxing, continued adherence to treatment, regular monitoring, and supportive care mean that many people with NMOSD are able to maintain independence and quality of life for years.

I hope this answers your query. Feel free to reach out anytime.

Thank you.